Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA modifications. The firm has curated a diverse pipeline targeting severe diseases, including genetic disorders and various cancers, addressing substantial unmet medical needs within the healthcare system. With a strong intellectual property foundation and a commitment to developing innovative therapeutic solutions, Prime Medicine is strategically positioned for notable growth and has the potential to significantly change therapeutic approaches in the biopharmaceutical industry.
| Revenue (TTM) | $4.07M |
| Gross Profit (TTM) | $-142.13M |
| EBITDA | $-189.12M |
| Operating Margin | -3751.00% |
| Return on Equity | -373.30% |
| Return on Assets | -46.50% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $0.23 |
| Price-to-Book | 0.40 |
| Price-to-Sales (TTM) | 207.07 |
| EV/Revenue | 211.93 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.50% |
| Shares Outstanding | $181.38M |
| Float | $112.25M |
| % Insiders | 20.30% |
| % Institutions | 71.31% |
Volatility is currently expanding
Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MONTREAL--(BUSINESS WIRE)--Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces the launch of a proposed private placement financing of subscription receipts for maximum aggregate gross proceeds of CA$4.0 million (the “Financing”) and that it has received a CA$2.5 million lead order from an institutional investor in connection with the Financing. Each subscription receipt will entitle the holder thereof, upon satisfaction of the Escrow Release Conditions (as defined below),.
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
Q4 historically delivers outsized S&P 500 returns, especially following midterm election years, supporting the 'October breakout cycle' thesis. Since 2000, the gains in the fourth quarter have averaged more than half of the S&P 500's annual returns with more positive years than all the other quarters. Small cap healthcare/biotech, technology, and consumer cyclicals—like PRME, CRNC, and FOSL—are highlighted as early breakout candidates with strong institutional interest and analyst targets.
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe --
-- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRME and any ticker you trade — then tracks every position and per-strategy win rate.
